Company: KROS
Filing Date: 2025-10-15
Form Type: SC TO-C
Source: 0001104659-25-099513
Chunk: 3

Company: Keros Therapeutics, Inc.
Filing Date: 2025-10-15
Form: SC TO-C
Chunk 3
---
 full financial statements
prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The Company’s independent registered public
accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary financial data or the accounting
treatment thereof and does not express an opinion or any other form of assurance with respect thereto. The Company expects to complete
its interim financial statements as of and for the quarter ended September 30, 2025 prior to the completion of the tender offer referenced
in Item 8.01 to this Current Report on Form 8-K. While the Company is currently unaware of any items that would require the Company
to make adjustments to the preceding preliminary unaudited financial information, it is possible that the Company or its independent registered
public accounting firm may identify such items as the Company completes its interim review process and any resulting changes could be
material. Accordingly, undue reliance should not be placed on this preliminary unaudited financial information. This preliminary unaudited
financial information is not necessarily indicative of any future period.

| 2 |

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In accordance with the terms
of the Pontifax Repurchase Agreement, each of Tomer Kariv and Ran Nussbaum have resigned from their respective positions as a member of
the Company’s board of directors and all committees thereof, effective as of October 15, 2025.

Following Mr. Kariv’s
resignation, the board of directors appointed Jean-Jacques Bienaimé, who currently serves as a member of the Nominating and Corporate
Governance Committee, as the new Chair of the Nominating and Corporate Governance Committee, effective October 15, 2025.

Item 7.01 Regulation FD Disclosure.

On October 15, 2025,
the Company issued a press release announcing several corporate updates, including, among other matters, (i) the execution of the
Repurchase Agreements and the related resignations of Tomer Kariv and Ran Nussbaum from the Company’s board of directors and all
committees thereof, and (ii) the Company’s intention to commence a tender offer. A copy of the press release is attached as
Exhibit 99.1 and incorporated herein by reference.

The information in this Item
7.01 to Current Report on Form 8-K, including Exhibit 99.